Participated · Series C · Jul 2026

Trellis Bioscience uses a proprietary technology to clone human antibodies from white blood cells and develops native human monoclonal antibodies to address difficult infectious diseases. Its lead program, calpurbatug (TRL1068), is an investigational monoclonal antibody aimed at disrupting biofilms and is in a Phase 2 trial for chronic prosthetic joint infections. The company also has a pipeline of antiviral antibodies, one of which is in a clinical trial. Trellis highlights that human antibodies have a lower toxicity-related failure rate than other drug classes and that its discovery approach isolates antibodies from recovered patients. The company is based in Redwood City, CA. To date Trellis has raised approximately $35 million in equity, complemented by a comparable amount of non-dilutive grant funding from NIAID and CARB-X.

Led · Series B · Oct 2023

Glydways builds autonomous electric Glydcars that operate on a two-metre-wide dedicated guideway called the Flow Network, designed to move up to 10,000 people per hour through lanes narrower than a parking space. The company says its system can be built at up to 90% lower cost than traditional rail while matching capacity, and emphasizes closed infrastructure to avoid safety issues tied to open-road autonomous vehicles. Founded in 2016 by Mark Seeger, Glydways is working on more than 20 projects globally and has begun construction on a public system in South Metro Atlanta. It has agreements for pilots in the UAE and plans additional pilots in the New York City area, with wider expansion planned for 2027. Glydways employs about 270 people and plans to double headcount over the next two years as it scales deployments.

Led · Equity · Feb 2023

Vuv Analytics is a Cedar Park, TX–based company that develops vacuum ultraviolet (VUV) detector technology for gas chromatography and automated analyzer applications. Its detectors are being incorporated into hydrocarbon and low-carbon industry standards, with four ASTM methods fully approved and three others entering ASTM and CEN ballots. The company’s devices are used by over 100 customers, including the top 10 U.S. oil refiners, the top four global test inspection and certification labs, and eight of the top 20 global chemical companies. Led by CEO Clark Jernigan, Vuv plans to use new funding to expand operations and broaden its business reach. Financially, the company has raised over $36M to date following the latest $20M financing. The product focus and customer traction support continued adoption in industry testing and standards. VUV Analytics develops vacuum ultraviolet (VUV) absorption spectroscopy instruments for gas chromatography and continuous gas monitoring. The company manufactures the VGA-100, VGA-101 and SVGA-100 gas chromatography and streaming gas detectors. Its products provide qualitative and quantitative data and enable continuous monitoring of gas purity and concentrations. VUV Analytics serves industries including environmental research, oil & gas, forensics, fragrances and flavors, petrochemical, specialty gas, agrochemical, food & beverage safety and life science. Led by CEO Clark Jernigan, the company says it will use the new financing to expand operations. Vivek Mohindra of New Science Ventures joined the company’s board as part of the round. VUV Analytics manufactures the VGA-100, a vacuum ultraviolet (VUV) absorption spectroscopy instrument. The VGA-100 is used for both qualitative and quantitative analysis and requires minimal calibration and sample preparation. Led by newly named CEO Clark Jernigan and founder and Senior VP of Business Development Sean Jameson, the company is focused on advancing its product and expanding adoption. VUV Analytics closed a $9m Series A and venture debt financing to support those efforts. The company intends to use the funds to further advance and expand adoption of its solutions. VUV Analytics is based in Austin, Texas. VUV Analytics is an Astin, Texas-based company that develops vacuum ultraviolet (VUV) optical spectroscopy instruments for the analytical sciences. Its instruments aim to deliver affordable lower detection limits (in some cases enabling detection) and more information content for characterization purposes. Led by CEO Sean Jameson, the company intends to launch a laboratory-scale molecular spectroscopy instruments business. In August 2012 VUV Analytics was selected as a Texas Emerging Technology Fund recipient. The company closed a $5.8M Series A equity funding to support its product launch and commercialization efforts. The financing is positioned to accelerate bringing VUV optical spectroscopy instruments to laboratory customers.

Participated · Series B · Nov 2022

Novadip Biosciences develops a 3M³ adipose-derived stem cell tissue regeneration platform intended to deliver one-time or off-the-shelf therapies for large bone defects and related orthopedic indications. Its lead allogeneic product, NVD-X3, is designed as an off-the-shelf matrix to accelerate durable bone union in spinal fusion and non-healing fractures and can be stored at room temperature for easy distribution. Its autologous program, NVD-003, targets critical-size bone defects such as congenital pseudarthrosis of the tibia (CPT) and is supported by Phase 1b/2a and compassionate-use data from more than 50 adult and pediatric patients with up to five years of follow-up. Novadip plans to initiate a Phase 1/2 trial for NVD-X3 in Europe and Phase 1b/2a CPT trials in the US and EU by end of 2022. NVD-003 has received orphan drug and rare pediatric disease designations from the FDA; if approved, the company could be eligible for a priority review voucher worth more than $100 million. The company estimates a $7 billion addressable market for its 3MALLO program and a $2.2 billion peak sales opportunity for NVD-X3; Novadip is headquartered in Mont Saint-Guibert, Belgium and was co-founded in 2013. Novadip Biosciences is a clinical-stage company leveraging its proprietary 3M³ 3D extracellular-matrix platform, which uses adipose-derived stem cells to deliver growth factors and miRNAs for tissue reconstruction. Its lead autologous product, NVD-003, has positive interim Phase I/IIa adult data and an FDA IND allowing a US pilot study in pediatric congenital pseudarthrosis of the tibia (ages 2–8). The company is also developing an allogeneic off-the-shelf product, NVD-X3, with a first clinical trial expected in 2022, and is exploring exosomal miRNA applications for solid tumors with trials planned in the US and Europe. Novadip was spun off from the University of Louvain (UCL) and Saint-Luc University Hospital and is advancing both autologous and allogeneic programs to address critical-size bone reconstruction and broader indications. The financing announced strengthens the balance sheet to support continued clinical development, platform innovation and potential future clinical paths in China. The company is based in Mont Saint-Guibert, Belgium. Novadip Biosciences is a biopharmaceutical spin‑off of Université catholique de Louvain advancing Creost, a ready‑to‑use natural three‑dimensional tissue that can be modelled to fill large and small bone defects. Creost will initially be investigated for complex lumbar spine fusion, an unmet medical need affecting more than 100,000 patients per year worldwide. The company plans to use the proceeds from its recent financing for clinical development and process industrialization of its lead compound. Leadership includes CEO and co‑founder Jean‑François Pollet and CSO and co‑founder Denis Dufrane. The technology originates from research led by Prof Denis Dufrane at the Cell and Tissue Therapy Centre of St Luc University Hospital and Université catholique de Louvain. Novadip closed a €28M Series A to fund these next development steps.

Led · Series B · Mar 2022

Paragraf develops graphene-based electronics and devices — including magnetic sensors and Graphene Molecular Sensors (GMS) — that integrate with standard semiconductor manufacturing processes. Its technology aims to deliver faster, more accurate, and lower-energy devices for extreme environments, from cryogenic quantum-computing systems to high-temperature, high-radiation industrial applications. Paragraf offers ready-to-use solutions and a platform for custom applications across healthcare, agritech, food production, chemical manufacturing, and consumer products. The company operates three facilities, two in Cambridgeshire, UK, and one in San Diego, US, following a 2023 acquisition. Paragraf is expanding its presence across the US, Europe, the Middle East, and Asia. The company recently completed a funding round intended to accelerate scaling and increase production capacity for commercial deployment of its graphene technologies. Paragraf develops commercial-quality graphene-based electronic devices using a contamination-free, scalable process that produces single-atom-thick, two-dimensional materials directly onto crystalline substrates such as silicon, silicon-carbide, sapphire and gallium-nitride. The technology is compatible with existing electronic device manufacturing processes. Its current product line includes a graphene Hall Effect Sensor range used across aerospace, semiconductor, healthcare, automotive, scientific research, industrial and quantum computing applications. The company is advancing a graphene-based biosensor targeted at transforming clinical point-of-care. Paragraf plans to use new funding to scale sales and technical capabilities in the UK, US, EU and Asia, boost R&D and product development capacity, and expand manufacturing infrastructure. The company has collaborated with CERN, the National Physical Laboratory and Rolls Royce and is led by CEO Dr Simon Thomas. Paragraf is a Cambridge, UK-based spin-out from the Centre for Gallium Nitride group at the University of Cambridge, led by CEO and co-founder Dr Simon Thomas. The company develops atom-layer-thick two-dimensional materials with a focus on graphene and holds an IP portfolio applying these materials to advanced electronic, energy and medical devices. Paragraf has achieved very early delivery to market of its first product, a super-high-sensitivity magnetic field detector. The detector offers operational capabilities over temperature, field and power ranges that no other device can currently achieve. The £3.4m Series A financing is intended to accelerate delivery of its first graphene-based electronics products to market. Paragraf, founded in 2015 as a University of Cambridge spin-out, develops graphene-based electronics and has built a manufacturing facility, graphene layer production and first device prototypes. Its first commercial product is a super-high-sensitivity magnetic field detector that the company says operates across temperature, field and power ranges unmatched by incumbents. The startup claims its IP-protected graphene technology can be produced using standard, mass-production scale manufacturing approaches and that its first sensors have shown order-of-magnitude operational improvements. Paragraf says it has strategic volume device production partners and is switching focus from development to product commercialisation. The company is transitioning into a commercial, revenue-generating phase supported by recent fundraising. CEO and co-founder Dr Simon Thomas stated the new funds will accelerate delivery and partnerships to bring devices to market. Paragraf has developed what it says is a novel, patent‑protected production technique intended to deliver functionally active graphene at commercial scale with improved uniformity, reproducibility, size and reduced contamination. Its core product focus is on producing atom‑layer thick 2D materials (starting with graphene) optimized for device‑specific applications, including sensitive detectors and improved contact layers for LEDs. The team claims the technique enables high quality and high throughput fabrication aimed at a new generation of electronic devices such as transistors, chemical and electrical sensors, and novel energy generation devices. Paragraf was spun out of Cambridge University’s Centre for Gallium Nitride group and, according to Crunchbase, was founded in 2015. The company closed a £2.9M (~$3.9M) seed round led by Cambridge Enterprise and intends to use follow‑on funding to scale development and deliver products from its IP pipeline. Management says it aims to deliver its first product by the end of the year and is planning a Series A raise expected in Q3 2019 to drive expanded development and product delivery.